ENSC - Latest News
Ensysce Biosciences, Inc. (ENSC), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $8.8M. Beta to the broader market is 1.02.
The article list below shows the most recent ENSC headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ENSC Headlines
Contrasting Hypermarcas (OTCMKTS:HYPMY) and Ensysce Biosciences (NASDAQ:ENSC)
defenseworld.net - Sep 29, 2026
Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and Hypermarcas (OTCMKTS:HYPMY - Get Free Report) are both healthcare companies, but which is the
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
accessnewswire.com - Sep 24, 2026
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
accessnewswire.com - Sep 15, 2026
SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechn
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
accessnewswire.com - Sep 14, 2026
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechn
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
accessnewswire.com - Sep 2, 2026
SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechno
How News Affects ENSC Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ENSC's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ENSC news questions
- What is the latest ENSC news headline?
- The most recent ENSC headline (Sep 29, 2026) is "Contrasting Hypermarcas (OTCMKTS:HYPMY) and Ensysce Biosciences (NASDAQ:ENSC)". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ENSC news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ENSC news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ENSC options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.